DOCSLIB.ORG

Pharmacological Interventions for Preventing Post-Traumatic Stress Disorder (PTSD) (Review)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacological Interventions for Preventing Post-Traumatic Stress Disorder (PTSD) (Review) Pharmacological interventions for preventing post-traumatic stress disorder (PTSD) (Review) Amos T, Stein DJ, Ipser JC This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2014, Issue 7 http://www.thecochranelibrary.com Pharmacological interventions for preventing post-traumatic stress disorder (PTSD) (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 13 Figure1. ..................................... 14 Figure2. ..................................... 17 Figure3. ..................................... 18 ADDITIONALSUMMARYOFFINDINGS . 23 DISCUSSION ..................................... 26 AUTHORS’CONCLUSIONS . 27 ACKNOWLEDGEMENTS . 28 REFERENCES ..................................... 28 CHARACTERISTICSOFSTUDIES . 33 DATAANDANALYSES. 56 Analysis 1.1. Comparison 1 Propranolol versus placebo, Outcome 1 Treatment efficacy. 56 Analysis 1.2. Comparison 1 Propranolol versus placebo, Outcome 2 Sensitivity analysis - observed cases. 57 Analysis 2.1. Comparison 2 Hydrocortisone versus placebo, Outcome 1 Treatment efficacy. 58 Analysis 2.2. Comparison 2 Hydrocortisone versus placebo, Outcome 2 Sensitivity analysis - observed cases. 59 APPENDICES ..................................... 59 HISTORY....................................... 62 CONTRIBUTIONSOFAUTHORS . 62 DECLARATIONSOFINTEREST . 63 SOURCESOFSUPPORT . 63 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 63 Pharmacological interventions for preventing post-traumatic stress disorder (PTSD) (Review) i Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Pharmacological interventions for preventing post-traumatic stress disorder (PTSD) Taryn Amos1, Dan J Stein1, Jonathan C Ipser1 1Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa Contact address: Taryn Amos, Department of Psychiatry and Mental Health, University of Cape Town, Education Centre, Valkenberg Hospital, Private Bage X1, Observatory, Cape Town, 7925, South Africa. [email protected]. Editorial group: Cochrane Depression, Anxiety and Neurosis Group. Publication status and date: New, published in Issue 7, 2014. Review content assessed as up-to-date: 14 February 2014. Citation: Amos T, Stein DJ, Ipser JC. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD006239. DOI: 10.1002/14651858.CD006239.pub2. Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ABSTRACT Background Post-traumatic stress disorder (PTSD) is a debilitating disorder which, after a sufficient delay, may be diagnosed amongst individuals who respond with intense fear, helplessness or horror to traumatic events. There is some evidence that the use of pharmacological interventions immediately after exposure to trauma may reduce the risk of developing of PTSD. Objectives To assess the effects of pharmacological interventions for the prevention of PTSD in adults following exposure to a traumatic event. Search methods We searched the Cochrane Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies and CCDANCTR- References) (to 14 February 2014). This register contains relevant reports of randomised controlled trials from the following bibliographic databases: CENTRAL (all years); EMBASE (1974 to date); MEDLINE (1950 to date) and PsycINFO (1967 to date). We identified unpublished trials by searching the National Institute of Health (NIH) Reporter, the metaRegister of Controlled Trials database (mRCT) and the WHO International Clinical Trials Registry Platform (to December 2013). We scanned the reference lists of articles for additional studies. We placed no constraints on language and setting. Selection criteria We restricted studies to randomised controlled trials (RCTs) of pharmacological interventions compared with placebo for the prevention of PTSD in adults. Data collection and analysis Two authors (TA and JI) independently assessed trials for eligibility and inclusion based on the review selection criteria. We independently extracted sample, methodological, outcome and ’Risk of bias’ data, as well as the number of side effects, from each trial and entered these into a customised data extraction form. We contacted investigators for missing information. We calculated summary statistics for continuous and dichotomous variables (if provided). We did not undertake subgroup analyses due to the small number of included studies. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD) (Review) 1 Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Main results We included nine short-term RCTs (duration 12 weeks or less) in the analysis (345 participants; age range 18 to 76 years). Participants were exposed to a variety of traumas, ranging from assault, traffic accidents and work accidents to cardiac surgery and septic shock. Seven studies were conducted at single centres. The seven RCTs included four hydrocortisone studies, three propranolol studies (of which one study had a third arm investigating gabapentin), and single trials of escitalopram and temazepam. Outcome assessment measures included the Clinician-Administered PTSD Scale (CAPS), the 36-Item Short-Form Health Survey (SF-36) and the Center for Epidemiological Studies - Depression Scale (CES-D). In four trials with 165 participants there was moderate quality evidence for the efficacy of hydrocortisone in preventing the onset of PTSD (risk ratio (RR) 0.17; 95% confidence interval (CI) 0.05 to 0.56; P value = 0.004), indicating that between seven and 13 patients would need to be treated with this agent in order to prevent the onset of PTSD in one patient. There was low quality evidence for preventing the onset of PTSD in three trials with 118 participants treated with propranolol (RR 0.62; 95% CI 0.24 to 1.59; P value = 0.32). Drop-outs due to treatment-emergent side effects, where reported, were low for all of the agents tested. Three of the four RCTs of hydrocortisone reported that medication was more effective than placebo in reducing PTSD symptoms after a median of 4.5 months after the event. None of the single trials of escitalopram, temazepam and gabapentin demonstrated evidence that medication was superior to placebo in preventing the onset of PTSD. Seven of the included RCTs were at a high risk of bias. Differential drop-outs between groups undermined the results of three studies, while one study failed to describe how the allocation of medication was concealed. Other forms of bias that might have influenced study results included possible confounding through group differences in concurrent medication and termination of the study based on treatment response. Authors’ conclusions There is moderate quality evidence for the efficacy of hydrocortisone for the prevention of PTSD development in adults. We found no evidence to support the efficacy of propranolol, escitalopram, temazepam and gabapentin in preventing PTSD onset. The findings, however, are based on a few small studies with multiple limitations. Further research is necessary in order to determine the efficacy of pharmacotherapy in preventing PTSD and to identify potential moderators of treatment effect. PLAIN LANGUAGE SUMMARY Medications to prevent post-traumatic stress disorder (PTSD): a review of the evidence Who may be interested in this review? - People affected by PTSD and their families. - Professionals working in adult mental health services. - General practitioners. - Charities that support victims of trauma or members of the armed forces. Why is this review important? PTSD is a condition experienced by some people after traumatic experiences such as warfare or domestic violence. People with PTSD experience symptoms of intense fear, helplessness and horror. Research suggests that changes in stress hormones in the brain may contribute to PTSD. Giving people medications which work in the brain soon after traumatic events may be able to prevent PTSD from developing. Previous reviews have shown that talking therapy (cognitive behavioural therapy - CBT) is effective in preventing PTSD. This is the first review of medication as a preventative treatment for PTSD. What questions does this review aim to answer? - Is medication an effective preventative treatment for PTSD compared to placebo (dummy pills)? - Is medication an acceptable treatment (do people stop medication due to side effects)? Which studies were included in the review? Pharmacological interventions for preventing post-traumatic stress disorder (PTSD) (Review) 2 Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. We searched databases to find all studies comparing medication with placebo for the prevention of PTSD, published up until February 2014. To be included in the review, studies had to be randomised controlled trials. Studies were included if they had adult participants aged over 18 who had experienced traumatic events but did not have a diagnosis of PTSD at the time
Load more

Recommended publications
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Introduction: Exploring the Boundaries of Obsessive-Compulsive Disorder
    Introduction Introduction Exploring the Boundaries of Obsessive-Compulsive Disorder and Other Anxiety Disorders Eric Hollander, M.D.; Joseph Zohar, M.D.; and Donatella Marazziti, M.D. Chairs of the International Obsessive-Compulsive Disorder Conference Organizing and Scientific Committee © Copyright 2002 Physicians Postgraduate Press, Inc. he Fifth International Obsessive-Compulsive Disorder Conference (5th IOCDC) took Tplace March 29 to April 1, 2001, in the spectacular setting of Sardinia, Italy. This supplement, “Exploring the Boundaries of Obsessive-Compulsive Disorder and Other Anx- iety Disorders: New Developments and Practical Approaches,” is an outgrowth and testa- ment to this exciting meeting and process. The IOCDC has been a premier ongoing series of meetings in the OCD field, bringing together international experts in selected topics of interest to OCD and related disorders. Various research initiatives,One personal such as the copy International may be Treatment-Refractoryprinted OCD Consor- tium and the International OCD Genetics Consortium, have been outgrowths of, and were facilitated by, this process. The 5th IOCDC focused on social anxiety disorder and general- ized anxiety disorder, as well as OCD. These meetings have been generously supported by an unrestricted educational grant from Solvay Pharmaceuticals. This supplement to The Journal of Clinical Psychiatry begins with an article by Nestadt and colleagues on defining the phenotype of OCD, which is essential for genetic and treat- ment studies of this syndrome. The authors describe a family-study approach that further validates the hypothesis that the phenotypic spectrum of OCD is relatively broad, including body dysmorphic disorder, hypochondriasis, and the grooming disorders as a group. This approach may also lead to the identification of more homogeneous subgroups within OCD.
    [Show full text]
  • Serotonin-1D Hypothesis of Obsessive-Compulsive Disorder: an Update
    Zohar et al. Serotonin-1D Hypothesis of Obsessive-Compulsive Disorder: An Update Joseph Zohar, M.D.; James L. Kennedy, M.D.; Eric Hollander, M.D.; and Lorrin M. Koran, M.D. Support for the serotonin-1D (5-HT1D) hypothesis of obsessive-compulsive disorder (OCD) and related conditions comes from a variety of sources. Some pharmacologic challenges with the 5-HT1D ago- nist sumatriptan, and case reports in which prolonged administration of 5-HT1D agonists was associated with a therapeutic effect, suggest that 5-HT1D may play a role in obsessive-compulsive symptoms. Ge- netic studies have also found that polymorphism of the 5-HT1D gene may be preferentially transmitted to those patients with OCD. However, taking into account that OCD is a heterogeneous syndrome, the 5-HT1D hypothesis requires further investigation in order to disentangle the role of the 5-HT1D receptor in this common and often severe disorder. (J Clin Psychiatry 2004;65[suppl 14]:18–21) he pathophysiology of most mental disorders has symptom changes following administration of lactate,7 T yet to be elucidated. One way to study pathophysi- carbon dioxide,8 yohimbine,9 and cholecystokinin receptor ology is by specific activation of the system or receptor(s) agonists10 suggests that OCD patients are not sensitive to hypothesized to be relevant, i.e., pharmacologic challenge. all anxiogenic challenges and that the serotonergic compo- A pharmacologic challenge is designed to induce a set nent of the m-CPP challenge may play a critical role in the of specific and relevant symptoms (e.g., exacerbation of pathology of OCD.
    [Show full text]
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit
    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
    [Show full text]
  • Discrimination Between Mechanism-Based Inactivation and Tight Binding Inhibitor Behavior
    Biomedical Chemistry: Research and Methods 2020, 3(1), e00115. DOI: 10.18097/bmcrm00115 1 EXPERIMENTAL RESEARCH A SIMPLE APPROACH FOR PILOT ANALYSIS OF TIME-DEPENDENT ENZYME INHIBITION: DISCRIMINATION BETWEEN MECHANISM-BASED INACTIVATION AND TIGHT BINDING INHIBITOR BEHAVIOR O.A. Buneeva, L.N. Aksenova, A.E. Medvedev* Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia; *e-mail: [email protected] The increase in enzyme inhibition developed during prolonged incubation of an enzyme preparation with a chemical substance may be associated with both the non-covalent and also with covalent enzyme-inhibitor complex formation. The latter case involves catalytic conversion of a mechanism-based irreversible inhibitor (a poor substrate) into a reactive species forming covalent adduct(s) with the enzyme and thus irreversibly inactivating the enzyme molecule. Using a simple approach, based on comparison of enzyme inhibition after preincubation with a potential inhibitor at 4ºC or 37ºC we have analyzed inhibition of monoamine oxidase A (MAO A) by known MAO inhibitors pargyline and pirlindole (pyrazidol). MAO A inhibitory activity of pirlindole (reversible tight binding inhibitor of MAO A) assayed after mitochondrial wash was basically the same for the incubation at both 4ºC and 37ºC. In contrast to pirlindole, the effect of pargyline (mechanism based irreversible MAO inhibitor) strongly depended on the temperature of the incubation medium. At 37ºC the residual activity MAO A in the mitochondrial fraction after washing was significantly lower than in the mitochondrial samples incubated with pargyline at 4ºC. Results of this study suggest that using analysis of both time- and temperature-dependence of inhibition it is possible to discriminate mechanism-based irreversible inhibition and reversible tight binding inhibition of target enzym Key words: enzyme inhibition; time-dependent and temperature-dependent inhibition; mechanism-based inhibitors; reversible tight binding inhibitors DOI: 10.18097/BMCRM00115 INTRODUCTION (England).
    [Show full text]
  • Attendee Guidelines
    (Temple of Eternal Sound) Attendee Guidelines 1. Introduction 2. Practical Guidelines -Preparation -Contraindications -Food -Clothing -Cleansing -During the Session -Suggested Best Practices -Temple Practices & Ritual Norms -Single Sacrament Sanctuary 3. Code of Ethics 4. Dietary Guidelines 5. Medical Information 6. Attendee Waiver Céu do Som Welcome, Thank you for your interest in our Forest Family Circles, Realisation Retreats and Wisdom Works at the Temple of Céu do Som & Abuelatree Sanctuary. You are endeavouring to participate in what, for us, is one of the most profound and meaningful doorways into the mysteries of the Sacred & Profound. The following pages are practical suggestions outlining our expectations, guidelines and safety measures to ensure harmony for you, for our work and for our community. We seek to uphold a high standard in regards to the safe space of transformation and realisation that may create a positive impact through healing and integration of our participants. The guidelines in this booklet all serve a direct purpose. We ask that each one be approached with due respect. It is not necessary to subscribe to our points of view in order to receive the sacrament. We do not discriminate and find that ultimately it is up to the individual to discover what is true for them. Así Céu do Som PRACTICAL GUIDELINES Preparation for the spiritual study Contraindications (refer to Medical Information section for more details) 1. If you are uncertain about any contraindications or factors please ask. 2. If you have any personal concerns a meeting can be arranged prior in order to discuss. 3. If you are taking any prescription medication, namely antidepressants, antipsychotics or SSRI's please speak to us (Refer to Medical Information section).
    [Show full text]
  • Joseph Zohar
    Joseph Zohar Joseph Zohar is director of psychiatry A and director of the Anxiety and Obsessive Compulsive Clinic at the Sheba Medical Center at Tel Hashomer in Israel. He graduated from Tel Aviv University Sackler School of Medicine in 1973, trained in psychiatry at the University of Washington, Seattle, and at the Jerusalem Mental Health Center in Israel, where he was the director of the Resistant Depression Unit. In 1984, he joined the laboratory of Dennis Murphy at the National Institute of Mental Health, Bethesda, Maryland, where he was acting director of the Obsessive-Compulsive Clinic. In 1986 he served as chairman of the panel for Obsessive-Compulsive Disorder of the American Psychiatric Association Task Force on Treatments of Psychiatric Disorders, and in 1989 as a member of the DSM-IV Obsessive Compulsive subcommittee. In 1992, Joseph Zohar established the International Council on Anxiety and OCD that is currently entitled World Council on Anxiety, and in 1993 he was nominated as the chairman of the anxiety and OCD section of the World Psychiatric Association (WPA) along with his role as the chairperson of the World Council on Anxiety. In 1994 he was the chairman of the 7th meeting of the European College of Neuropsychopharmacology (ECNP) and in 1995 was elected as a member of the executive committee of the College and chairman of the Israel Society for Biological Psychiatry. In 1996 he was nominated as a member of the WHO Expert Advisory Panel on Neuroscience. In 1997 he was elected to the executive committee of the World Federation of Societies of Biological Psychiatry.
    [Show full text]
  • Obsessive-Compulsive Disorder, Second Edition (WPA Series In
    VOLUME 4 Obsessive-Compulsive Disorder Second Edition Edited by Mario Maj University of Naples, Italy Norman Sartorius University of Geneva, Switzerland Ahmed Okasha Ain Shams University, Cairo, Egypt Joseph Zohar Tel Aviv University, Israel WPA Series Evidence and Experience in Psychiatry VOLUME 4 Obsessive-Compulsive Disorder Second Edition WPA Series Evidence and Experience in Psychiatry Other Titles in the WPA Series Evidence and Experience in Psychiatry Volume 1ÐDepressive Disorders, Second Edition Mario Maj and Norman Sartorius Volume 2ÐSchizophrenia, Second Edition Mario Maj and Norman Sartorius Volume 3ÐDementia, Second Edition Mario Maj and Norman Sartorius Volume 5ÐBipolar Disorder Mario Maj, Hagop S. Akiskal, Juan Jose LoÂpez-Ibor and Norman Sartorius VOLUME 4 Obsessive-Compulsive Disorder Second Edition Edited by Mario Maj University of Naples, Italy Norman Sartorius University of Geneva, Switzerland Ahmed Okasha Ain Shams University, Cairo, Egypt Joseph Zohar Tel Aviv University, Israel WPA Series Evidence and Experience in Psychiatry Copyright # 2002 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777 Email (for orders and customer service enquiries): [email protected] Visit our Home Page on www.wileyeurope.com or www.wiley.com First Edition printed in 2000. All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patients Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher.
    [Show full text]
  • Guidelines for the Pharmacological Treatment of Anxiety Disorders, Obsessive– Compulsive Disorder and Posttraumatic Stress Disorder in Primary Care
    International Journal of Psychiatry in Clinical Practice, 2012; 16: 77–84 REVIEW ARTICLE Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care BORWIN BANDELOW 1 , LEO SHER 2 , ROBERTAS BUNEVICIUS 3 , ERIC HOLLANDER 2 , SIEGFRIED KASPER 4 , JOSEPH ZOHAR 5 , HANS-J Ü RGEN M Ö LLER 6 , WFSBP TASK FORCE ON MENTAL DISORDERS IN PRIMARY CARE a AND WFSBP TASK FORCE ON ANXIETY DISORDERS , OCD AND PTSD b 1 Department of Psychiatry and Psychotherapy, University of G ö ttingen, Gö ttingen, Germany, 2 Albert Einstein College of Medicine and Montefi ore Medical Center, New York City, NY, USA, 3 Institute of Psychophysiology and Rehabilitation, Lithuanian University of Health Sciences, Palanga, Lithuania, 4 Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, 5 Division of Psychiatry, Chaim-Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, and 6 Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany Abstract Objective. Anxiety disorders are frequently under-diagnosed conditions in primary care, although they can be managed effectively by general practitioners. Methods. This paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety disorders, obsessive– compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) for the treatment in primary care. The recommendations were developed by a task force of 30 international experts in the fi eld and are based on randomized controlled studies. Results. First-line pharmacological treatments for these disorders are selective serotonin reuptake inhibitors (for all disor- ders), serotonin-norepinephrine reuptake inhibitors (for some) and pregabalin (for generalized anxiety disorder only).
    [Show full text]
  • Dawson, S., Maund, E., Stuart, B., Moore, M., Christopher, D
    Dawson, S. , Maund, E., Stuart, B., Moore, M., Christopher, D., Geraghty, A. WA., & Kendrick, T. (2019). Managing Antidepressant Discontinuation: A Systematic Review. Annals of Family Medicine, 17(1), 52-60. https://doi.org/10.1370/afm.2336 Peer reviewed version License (if available): Other Link to published version (if available): 10.1370/afm.2336 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the Annals of Family Medicine at https://doi.org/10.1370/afm.2336 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Supplemental materials for: Maund E, Stuart B, Moore M, et al. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52-60. 1 Supplemental APPENDIX 1 - SEARCH STRATEGIES MEDLINE Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 23 March 2017 Search Query Items ID# found 1 exp ANTIDEPRESSIVE AGENTS/ 133782 2 exp NEUROTRANSMITTER UPTAKE INHIBITORS/ 133192 3 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 136112 noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,kf,hw.
    [Show full text]
  • Comparison of Criminal Activity Between Israeli Veterans with and Without PTSD
    Sherman, S., Fostick, L. , Zohar, J. (accepted). Comparison of Criminal Activity between Israeli Veterans with and Without PTSD. Depression and Anxiety . ***This is a self-archiving copy and does not fully replicate the published version*** Comparison of Criminal Activity between Israeli Veterans with and Without PTSD Shany Sherman *1 , Leah Fostick *2 , Joseph Zohar 1, 3 , on behalf of the Israeli Consortium on PTSD † 1 – Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2 – Ariel University, Ariel, Israel 3 – Department of Psychiatry, Chaim Sheba Medical Center, Tel Hashomer, Israel * - Shany Sherman and Leah Fostick are acknowledged to have made an equal contribution to the manuscript. † - The Israeli Consortium on PTSD includes: Zohar J(chair), Bleich A, Kaplan Z, Katz I, Klein E, Kotler M, Shalev AY, Ohry A, and Weissman Z. Address for correspondence: Dr. J. Zohar; Department of Psychiatry; Sheba Medical Center; Tel Hashomer; Israel. Telephone: 972-3530-3300. Fax: 972-3535-2788. Email: [email protected]. Zohar J has received grant/research support from Lundbeck, Servier and Pfizer, has served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Actelion, AstraZeneca and Roche, and has served on speakers’ bureaus for Lundbeck, GSK, AstraZeneca and Abbott. ZOHAR JOSEPH This study was partially supported by a grant from the Rehabilitation Center of the Israeli Ministry of Defense. Key words Posttraumatic stress disorder; Veterans; Military; Violence; Criminal record 2 ZOHAR JOSEPH Abstract Background: The literature, based on US Vietnam veterans, suggests that PTSD is associated with increased criminal activity, especially violence, alcohol and drug abuse, although more recent studies, which tested data from the US as well as the UK, suggest a more moderate effect for this relationship.
    [Show full text]
  • Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms
    PROTEOSTASIS OF GLIAL INTERMEDIATE FILAMENTS: DISEASE MODELS, TOOLS, AND MECHANISMS Rachel Anne Battaglia A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Cell Biology and Physiology in the School of Medicine. Chapel Hill 2021 Approved by: Natasha T. Snider Carol Otey Keith Burridge Douglas Cyr Mohanish Deshmukh Damaris Lorenzo i © 2021 Rachel Anne Battaglia ALL RIGHTS RESERVED ii ABSTRACT Rachel Anne Battaglia: Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms (Under the direction of Natasha T. Snider) Astrocytes are a major glial cell type that is crucial for the health and maintenance of the Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) are components of the astrocyte cytoskeleton that support many of these functions in healthy individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to accumulation and aggregation. These processes are thought to contribute to disease pathogenesis of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of pharmacological tools to modulate their assembly and disassembly states. Moreover, the mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post- translational modifications (PTMs) in this process.
    [Show full text]